Related Experiment Video
Updated: Jul 26, 2026
06:40
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
Published on: October 24, 2014
Noninvasive gene targeting to the brain
1Department of Medicine, University of California School of Medicine, Los Angeles, CA 90095-1682, USA.
Summary
Noninvasive gene therapy for the brain is now possible. Researchers developed neutral immunoliposomes that target the transferrin receptor, enabling gene delivery across the blood-brain barrier (BBB) after intravenous administration.
Area of Science:
- Neuroscience
- Biotechnology
- Gene Therapy
Background:
- The blood-brain barrier (BBB) restricts the delivery of therapeutic agents, including gene formulations, to the brain.
- Previous brain gene therapy methods required invasive procedures like craniotomy or disruptive intracarotid infusions.
Purpose of the Study:
- To investigate the efficacy of noninvasive intravenous gene delivery to the brain using targeted immunoliposomes.
- To evaluate the expression of exogenous genes in the brain following this novel delivery method.
Main Methods:
- Development of neutral pegylated immunoliposomes conjugated with the OX26 mAb targeting the rat transferrin receptor.
- Encapsulation of 6- to 7-kb expression plasmids encoding luciferase or beta-galactosidase within the immunoliposomes.
- Noninvasive intravenous administration of the gene formulation to adult rats.
Main Results:
- Successful expression of luciferase and beta-galactosidase genes in the brain after a single intravenous dose.
- Gene expression peaked at 48 hours post-administration with a significantly lower DNA dose compared to cationic liposomes.
- Histochemistry confirmed widespread gene expression throughout the central nervous system, including neurons and vasculature.
Conclusions:
- Neutral immunoliposomes can effectively target the BBB's transferrin receptor for noninvasive gene delivery.
- This method bypasses the need for viruses or cationic liposomes, offering a safer alternative for brain gene therapy.
- Endogenous receptor-mediated transport pathways can be leveraged for widespread gene expression in the brain.
